Stratification by tumor typeand biomarkers could also be important and was highlighted in a clinicaltrial of CV92027, where patients were stratified by NSCLC subtype(squamous versus nonsquamous) and EGFR-mutation status., The BNT116 trial specifically enrolled patients with NSCLC thatfrail with PD-L1 ≥ 1%, acknowledging that mRNA vaccines maywork best in those already prone to immunogenic tumors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.